4.7 Article

Clinical Features and Outcomes of 105 Hospitalized Patients With COVID-19 in Seattle, Washington

期刊

CLINICAL INFECTIOUS DISEASES
卷 71, 期 16, 页码 2167-2173

出版社

OXFORD UNIV PRESS INC
DOI: 10.1093/cid/ciaa632

关键词

COVID-19; SARS-CoV-2; outcomes; hospitalized; comorbidities

资金

  1. National Institute of Allergy and Infectious Diseases [5T32AI007044]

向作者/读者索取更多资源

Background. Washington State served as the initial epicenter of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic in the United States. An understanding of the risk factors and clinical outcomes of hospitalized patients with coronavirus disease 2019 (COVID-19) may provide guidance for management. Methods. All laboratory-confirmed COVID-19 cases in adults admitted to an academic medical center in Seattle, Washington, between 2 March and 26 March 2020 were included. We evaluated individuals with and without severe disease, defined as admission to the intensive care unit or death. Results. One hundred five COVID-19 patients were hospitalized. Thirty-five percent were admitted from a senior home or skilled nursing facility. The median age was 69 years, and half were women. Three or more comorbidities were present in 55% of patients, with hypertension (59%), obesity (47%), cardiovascular disease (38%), and diabetes (33%) being the most prevalent. Most (63%) had symptoms for >= 5 days prior to admission. Only 39% had fever in the first 24 hours, whereas 41% had hypoxia at admission. Seventy-three percent of patients had lymphopenia. Of 50 samples available for additional testing, no viral coinfections were identified. Severe disease occurred in 49%. Eighteen percent of patients were placed on mechanical ventilation, and the overall mortality rate was 33%. Conclusions. During the early days of the COVID-19 epidemic in Washington State, the disease had its greatest impact on elderly patients with medical comorbidities. We observed high rates of severe disease and mortality in our hospitalized patients.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Multidisciplinary Sciences

Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift

Elisabetta Cameroni, John E. Bowen, Laura E. Rosen, Christian Saliba, Samantha K. Zepeda, Katja Culap, Dora Pinto, Laura A. VanBlargan, Anna De Marco, Julia di Iulio, Fabrizia Zatta, Hannah Kaiser, Julia Noack, Nisar Farhat, Nadine Czudnochowski, Colin Havenar-Daughton, Kaitlin R. Sprouse, Josh R. Dillen, Abigail E. Powell, Alex Chen, Cyrus Maher, Li Yin, David Sun, Leah Soriaga, Jessica Bassi, Chiara Silacci-Fregni, Claes Gustafsson, Nicholas M. Franko, Jenni Logue, Najeeha Talat Iqbal, Ignacio Mazzitelli, Jorge Geffner, Renata Grifantini, Helen Chu, Andrea Gori, Agostino Riva, Olivier Giannini, Alessandro Ceschi, Paolo Ferrari, Pietro E. Cippa, Alessandra Franzetti-Pellanda, Christian Garzoni, Peter J. Halfmann, Yoshihiro Kawaoka, Christy Hebner, Lisa A. Purcell, Luca Piccoli, Matteo Samuele Pizzuto, Alexandra C. Walls, Michael S. Diamond, Amalio Telenti, Herbert W. Virgin, Antonio Lanzavecchia, Gyorgy Snell, David Veesler, Davide Corti

Summary: The Omicron variant of SARS-CoV-2 has raised concerns due to its 37 amino acid substitutions in the spike protein, particularly in the receptor-binding domain (RBD), leading to increased binding affinity with human ACE2. Neutralizing activity against Omicron was greatly reduced in convalescent and vaccinated individuals compared to the ancestral virus, but this decrease was less significant after a third vaccine dose. Broadly neutralizing monoclonal antibodies recognizing conserved RBD epitopes may be crucial in combating the Omicron variant and future zoonotic transmissions.

NATURE (2022)

Letter Biochemistry & Molecular Biology

The Seattle Flu Study: when regulations hinder pandemic surveillance

Michael Boeckh, Helen Y. Chu, Janet A. Englund, Christina M. Lockwood, Deborah A. Nickerson, Jay Shendure, Lea Starita

NATURE MEDICINE (2022)

Article Pediatrics

Mobilizing Established School Partnerships to Reach Underserved Children During a Global Pandemic

Linda K. Ko, Lauren Tingey, Magaly Ramirez, Elliott Pablo, Ryan Grass, Francene Larzelere, Oralia Cisneros, Helen Y. Chu, Emily M. D'Agostino

Summary: Using diagnostic testing approaches in schools can accelerate the safe return of students and staff, prevent the spread of COVID-19, and reduce school and work absenteeism. However, the application of community-based participatory research (CBPR) approach in school engagement is limited. This article provides case studies of school-academic partnerships built on CBPR processes and practices, serving as research infrastructure to reach underserved children and families during the pandemic.

PEDIATRICS (2022)

Article Immunology

Trends in COVID-19 vaccination intent and factors associated with deliberation and reluctance among adult homeless shelter residents and staff, 1 November 2020 to 28 February 2021-King County, Washington

Julia H. Rogers, Sarah N. Cox, James P. Hughes, Amy C. Link, Eric J. Chow, Idabelle Fosse, Margaret Lukoff, M. Mia Shim, Timothy M. Uyeki, Constance Ogokeh, Michael L. Jackson, Michael Boeckh, Janet A. Englund, Emily Mosites, Melissa A. Rolfes, Helen Y. Chu

Summary: This study found significant disparities in COVID-19 vaccination intent among homeless individuals based on race, education level, and prior vaccine history. There was no observed trend towards increased vaccine acceptance over the study period.

VACCINE (2022)

Article Microbiology

The SARS-CoV-2 Delta variant induces an antibody response largely focused on class 1 and 2 antibody epitopes

Allison J. Greaney, Rachel T. Eguia, Tyler N. Starr, Khadija Khan, Nicholas Franko, Jennifer K. Logue, Sandra M. Lord, Cate Speake, Helen Y. Chu, Alex Sigal, Jesse D. Bloom

Summary: Exposure to SARS-CoV-2 variants and vaccinations affects the specificity of antibody responses. The Delta variant elicits a neutralizing antibody response focused on the receptor-binding domain, similar to early 2020 viruses but different from the Beta variant. Mutations to the class 1 epitope have a significant impact on antibody binding and neutralization in the Delta spike.

PLOS PATHOGENS (2022)

Article Medicine, General & Internal

Estimated Global Proportions of Individuals With Persistent Fatigue, Cognitive, and Respiratory Symptom Clusters Following Symptomatic COVID-19 in 2020 and 2021

Sarah Wulf Hanson, Cristiana Abbafati, Joachim G. Aerts, Ziyad Al-Aly, Charlie Ashbaugh, Tala Ballouz, Oleg Blyuss, Polina Bobkova, Gouke Bonsel, Svetlana Borzakova, Danilo Buonsenso, Denis Butnaru, Austin Carter, Helen Chu, Cristina De Rose, Mohamed Mustafa Diab, Emil Ekbom, Maha El Tantawi, Victor Fomin, Robert Frithiof, Aysylu Gamirova, Petr Glybochko, Juanita A. Haagsma, Shaghayegh Haghjooy Javanmard, Erin B. Hamilton, Gabrielle Harris, Majanka H. Heijenbrok-Kal, Raimund Helbok, Merel E. Hellemons, David Hillus, Susanne M. Huijts, Michael Hultstrom, Waasila Jassat, Florian Kurth, Ing-Marie Larsson, Miklos Lipcsey, Chelsea Liu, Callan D. Loflin, Andrei Malinovschi, Wenhui Mao, Lyudmila Mazankova, Denise McCulloch, Dominik Menges, Noushin Mohammadifard, Daniel Munblit, Nikita A. Nekliudov, Osondu Ogbuoji, Ismail M. Osmanov, Jose L. Penalvo, Maria Skaalum Petersen, Milo A. Puhan, Mujibur Rahman, Verena Rass, Nickolas Reinig, Gerard M. Ribbers, Antonia Ricchiuto, Sten Rubertsson, Elmira Samitova, Nizal Sarrafzadegan, Anastasia Shikhaleva, Kyle E. Simpson, Dario Sinatti, Joan B. Soriano, Ekaterina Spiridonova, Fridolin Steinbeis, Andrey A. Svistunov, Piero Valentini, Brittney J. van de Water, Rita Van den Berg-Emons, Ewa Wallin, Martin Witzenrath, Yifan Wu, Hanzhang Xu, Thomas Zoller, Christopher Adolph, James Albright, Joanne O. Amlag, Aleksandr Y. Aravkin, Bree L. Bang-Jensen, Catherine Bisignano, Rachel Castellano, Emma Castro, Suman Chakrabarti, James K. Collins, Xiaochen Dai, Farah Daoud, Carolyn Dapper, Amanda Deen, Bruce B. Duncan, Megan Erickson, Samuel B. Ewald, Alize J. Ferrari, Abraham D. Flaxman, Nancy Fullman, Amiran Gamkrelidze, John R. Giles, Gaorui Guo, Simon Hay, Jiawei He, Monika Helak, Erin N. Hulland, Maia Kereselidze, Kris J. Krohn, Alice Lazzar-Atwood, Akiaja Lindstrom, Rafael Lozano, Deborah Carvalho Malta, Johan Mansson, Ana M. Mantilla Herrera, Ali H. Mokdad, Lorenzo Monasta, Shuhei Nomura, Maja Pasovic, David M. Pigott, Robert C. Reiner Jr, Grace Reinke, Antonio Luiz P. Ribeiro, Damian Francesco Santomauro, Aleksei Sholokhov, Emma Elizabeth Spurlock, Rebecca Walcott, Ally Walker, Charles Shey Wiysonge, Peng Zheng, Janet Prvu Bettger, Christopher J. L. Murray, Theo Vos

Summary: This study estimated the proportion and duration of Long COVID symptoms in individuals with symptomatic SARS-CoV-2 infection in 2020 and 2021. The results showed differences in the prevalence and duration of Long COVID symptoms across different age and gender groups.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2022)

Review Microbiology

The effects of the COVID-19 pandemic on community respiratory virus activity

Eric J. Chow, Timothy M. Uyeki, Helen Y. Chu

Summary: The COVID-19 pandemic has significantly affected global respiratory virus infections, with varying degrees of changes seen in different virus types. Non-pharmaceutical interventions have been implemented by governments, with differences observed after the availability of COVID-19 vaccines. Reductions in respiratory virus infections have resulted in decreased hospitalizations and deaths associated with these infections.

NATURE REVIEWS MICROBIOLOGY (2023)

Article Multidisciplinary Sciences

Imprinted antibody responses against SARS-CoV-2 Omicron sublineages

Young-Jun Park, Dora Pinto, Alexandra C. Walls, Zhuoming Liu, Anna De Marco, Fabio Benigni, Fabrizia Zatta, Chiara Silacci-Fregni, Jessica Bassi, Kaitlin R. Sprouse, Amin Addetia, John E. Bowen, Cameron Stewart, Martina Giurdanella, Christian Saliba, Barbara Guarino, Michael A. Schmid, Nicholas M. Franko, Jennifer K. Logue, Ha V. Dang, Kevin Hauser, Julia di Iulio, William Rivera, Gretja Schnell, Anushka Rajesh, Jiayi Zhou, Nisar Farhat, Hannah Kaiser, Martin Montiel-Ruiz, Julia Noack, Florian A. Lempp, Javier Janer, Rana Abdelnabi, Piet Maes, Paolo Ferrari, Alessandro Ceschi, Olivier Giannini, Guilherme Dias De Melo, Lauriane Kergoat, Herve Bourhy, Johan Neyts, Leah Soriaga, Lisa A. Purcell, Gyorgy Snell, Sean P. J. Whelan, Antonio Lanzavecchia, Herbert W. Virgin, Luca Piccoli, Helen Y. Chu, Matteo Samuele Pizzuto, Davide Corti, David Veesler

Summary: SARS-CoV-2 Omicron sublineages have spike mutations that allow them to evade antibodies from previous infection or vaccination. Hybrid immunity or booster shots can generate neutralizing antibodies against Omicron variants, and breakthrough infections lead to the production of neutralizing antibodies in the nasal mucosa. Antibodies derived from memory B cells or plasma cells of Omicron breakthrough cases show cross-reactivity with different receptor-binding domains, while primary Omicron infections elicit B cells with narrow specificity. A highly potent pan-variant-neutralizing antibody has been identified as a potential candidate for clinical development.

SCIENCE (2022)

Article Immunology

Reinfection with SARS-CoV-2 and Waning Humoral Immunity: A Case Report

Jason D. Goldman, Kai Wang, Katharina Roltgen, Sandra C. A. Nielsen, Jared C. Roach, Samia N. Naccache, Fan Yang, Oliver F. Wirz, Kathryn E. Yost, Ji-Yeun Lee, Kelly Chun, Terri Wrin, Christos J. Petropoulos, Inyoul Lee, Shannon Fallen, Paula M. Manner, Julie A. Wallick, Heather A. Algren, Kim M. Murray, Jennifer Hadlock, Daniel Chen, Chengzhen L. Dai, Dan Yuan, Yapeng Su, Joshua Jeharajah, William R. Berrington, George P. Pappas, Sonam T. Nyatsatsang, Alexander L. Greninger, Ansuman T. Satpathy, John S. Pauk, Scott D. Boyd, James R. Heath

Summary: Recovery from COVID-19 does not guarantee immunity, as reinfection with a different strain can occur. In this study, we present a case of reinfection with a variant strain carrying the D614G mutation. By analyzing antibodies, B cells, and T cells, we provide evidence of adaptive immunity during reinfection. Our findings have implications for vaccine programs and establishing benchmarks for protection against SARS-CoV-2 reinfection.

VACCINES (2023)

Article Infectious Diseases

Respiratory syncytial virus and other respiratory virus infections in residents of homeless shelters - King County, Washington, 2019-2021

Denise J. McCulloch, Julia H. Rogers, Yongzhe Wang, Eric J. Chow, Amy C. Link, Caitlin R. Wolf, Timothy M. Uyeki, Melissa A. Rolfes, Emily Mosites, Jaydee Sereewit, Jeffrey S. Duchin, Nancy K. Sugg, Alexander L. Greninger, Michael J. Boeckh, Janet A. Englund, Jay Shendure, James P. Hughes, Lea M. Starita, Pavitra Roychoudhury, Helen Y. Chu

Summary: Respiratory syncytial virus (RSV) causes disproportionate morbidity and mortality in vulnerable populations. In a study conducted in homeless shelters in Seattle, RSV was detected in 35 out of 15,364 tested specimens, compared to 77 cases of influenza. Both RSV and influenza showed similar symptoms of cough and rhinorrhea, and significantly impacted individuals' ability to perform regular activities.

INFLUENZA AND OTHER RESPIRATORY VIRUSES (2023)

Article Virology

Dynamics of SARS-CoV-2 VOC Neutralization and Novel mAb Reveal Protection against Omicron

Linhui Hao, Tien-Ying Hsiang, Ronit R. Dalmat, Renee Ireton, Jennifer F. Morton, Caleb Stokes, Jason Netland, Malika Hale, Chris Thouvenel, Anna Wald, Nicholas M. Franko, Kristen Huden, Helen Y. Chu, Alex Sigal, Alex L. Greninger, Sasha Tilles, Lynn K. Barrett, Wesley C. Van Voorhis, Jennifer Munt, Trevor Scobey, Ralph S. Baric, David J. Rawlings, Marion Pepper, Paul K. Drain, Michael Gale

Summary: New variants of SARS-CoV-2 continue to emerge and evade immunity. Convalescence from the ancestral virus provides limited protection against variants. Vaccination enhances immunity against viral variants, but the protection is weaker against Omicron BA.1, and a three-dose vaccine regimen provides significantly better protection against it compared to a two-dose.

VIRUSES-BASEL (2023)

Article Immunology

Successful Treatment of Persistent Symptomatic Coronavirus Disease 19 Infection With Extended-Duration Nirmatrelvir-Ritonavir Among Outpatients With Hematologic Cancer

Catherine Liu, Leah H. Yoke, Pooja Bhattacharyya, Ryan D. Cassaday, Guang-Shing Cheng, Zahra Kassamali Escobar, Cristina Ghiuzeli, Denise J. McCulloch, Steven A. Pergam, Pavitra Roychoudhury, Frank Tverdek, Joshua T. Schiffer, Emily S. Ford

Summary: Persistent symptomatic COVID-19 in patients with hematologic cancer and/or profound immunosuppression is challenging to manage. Two patients with symptomatic COVID-19 for almost 6 months were successfully treated in the ambulatory setting with extended courses of nirmatrelvir-ritonavir. B-cell dysfunction may contribute to the persistence of COVID-19 infection in immunosuppressed individuals, and nirmatrelvir/ritonavir could be an effective treatment option.

OPEN FORUM INFECTIOUS DISEASES (2023)

Article Immunology

Antiviral Prescribing Among Patients at an Ambulatory Cancer Center With Laboratory-Confirmed Influenza

Woody Sorey, Elizabeth M. Krantz, Jessica Morris, John Klaassen, Ania Sweet, Frank Tverdek, Zahra K. Escobar, Denise J. McCulloch, Steven A. Pergam, Catherine Liu

Summary: Among 133 cancer outpatients diagnosed with influenza between 2016 and 2018, 83% were prescribed oseltamivir. Among 109 with a known symptom onset date, 53% presented for care and 31% were prescribed oseltamivir within 48 hours. Patient/provider education and rapid diagnostics are needed to improve early oseltamivir use among cancer patients with influenza.

OPEN FORUM INFECTIOUS DISEASES (2023)

Article Multidisciplinary Sciences

Neutralization, effector function and immune imprinting of Omicron variants

Amin Addetia, Luca Piccoli, James Brett Case, Young-Jun Park, Martina Beltramello, Barbara Guarino, Ha Dang, Guilherme Dias de Melo, Dora Pinto, Kaitlin Sprouse, Suzanne M. Scheaffer, Jessica Bassi, Chiara Silacci-Fregni, Francesco Muoio, Marco Dini, Lucia Vincenzetti, Rima Acosta, Daisy Johnson, Sambhavi Subramanian, Christian Saliba, Martina Giurdanella, Gloria Lombardo, Giada Leoni, Katja Culap, Carley Mcalister, Anushka Rajesh, Exequiel Dellota, Jiayi Zhou, Nisar Farhat, Dana Bohan, Julia Noack, Alex Chen, Florian A. Lempp, Joel Quispe, Lauriane Kergoat, Florence Larrous, Elisabetta Cameroni, Bradley Whitener, Olivier Giannini, Pietro Cippa, Alessandro Ceschi, Paolo Ferrari, Alessandra Franzetti-Pellanda, Maira Biggiogero, Christian Garzoni, Stephanie Zappi, Luca Bernasconi, Min Jeong Kim, Laura E. Rosen, Gretja Schnell, Nadine Czudnochowski, Fabio Benigni, Nicholas Franko, Jennifer K. Logue, Courtney Yoshiyama, Cameron Stewart, Helen Chu, Herve Bourhy, Michael A. Schmid, Lisa A. Purcell, Gyorgy Snell, Antonio Lanzavecchia, Michael S. Diamond, Davide Corti, David Veesler

Summary: The recently emerged BQ.1.1 and XBB.1.5 variants of SARS-CoV-2 have a higher affinity for the host ACE2 receptor and more efficiently promote fusion with host cell membranes compared to earlier Omicron variants. Although the neutralizing activity is reduced, vaccine-induced human plasma antibodies still cross-react with and trigger effector functions against current Omicron variants, providing a mechanism of protection against disease.

NATURE (2023)

Article Infectious Diseases

Acute respiratory infections among individuals seeking outpatient care in the states of Washington and Michigan by pregnancy status, 2011-2016

Collrane Frivold, Denise J. Mcculloch, Seda Ekici, Emily T. Martin, Michael L. Jackson, Helen Y. Chu

Summary: Acute respiratory infections (ARIs) during pregnancy are associated with poor maternal and fetal outcomes. By testing for respiratory viruses among pregnant and non-pregnant individuals, we found differences in virus detection based on pregnancy status.

INFLUENZA AND OTHER RESPIRATORY VIRUSES (2023)

暂无数据